Radiation and immunotherapy join forces against tough pancreatic cancer
NCT ID NCT07312422
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 23 times
Summary
This early-phase study is testing whether adding low-dose radiation and an immunotherapy drug called pucotenlimab to standard chemotherapy can help control advanced pancreatic cancer. Ten adults with pancreatic cancer who haven't had prior immunotherapy will receive the combination. The goal is to see if the treatment shrinks tumors and improves disease control, while also identifying which patients benefit most.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Provincial People's Hospital
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
low-dose radiation, pucotenlimab (a PD-1 inhibitor), gemcitabine, nab-paclitaxel, oxaliplatin, irinotecan, leucovorin, and 5-FU
What this could lead to
If it works, this could point toward a new combination therapy that helps control advanced pancreatic cancer by activating the immune system.
What could go wrong
This is a very early, small trial with only 10 participants, so results may not apply widely. The combination also carries risks like immune-related side effects and chemotherapy toxicity.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.